Primary Research Focus
Research on Semax centers on its ability to upregulate brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus and cortex, modulate monoamine neurotransmitter systems (dopamine and serotonin), and exert neuroprotective effects in models of cerebral ischemia. These actions support investigations into synaptic plasticity, neuronal survival, and recovery after ischemic injury.
Regulatory and Research Status
Semax is registered as a prescription medication in Russia (intranasal formulations) for certain neurological indications, including aspects of ischemic stroke recovery and cognitive impairment. It is not approved by the U.S. FDA, EMA, or equivalent Western regulatory bodies and is available outside Russia only as a research chemical for laboratory and preclinical investigation. All information here is provided strictly for educational and research purposes.
Chemical Structure and Design Rationale
Semax (molecular formula C₃₇H₅₁N₉O₁₀S, molecular weight approximately 813.9 g/mol) consists of the tetrapeptide core Met-Glu-His-Phe derived from ACTH residues 4–7, followed by the stabilizing tripeptide Pro-Gly-Pro. The Pro-Gly-Pro extension confers resistance to proteolytic degradation, extending the peptide’s functional half-life compared with the native ACTH fragment, which is rapidly broken down. Critically, this modification abolishes the ability of the parent hormone to stimulate the hypothalamic-pituitary-adrenal axis, allowing researchers to isolate central nervous system effects without confounding endocrine activity. The peptide is typically administered intranasally in research and clinical contexts in Russia, a route that facilitates direct access to CNS structures via olfactory pathways.
Mechanisms of Action Supported by Research
The most consistently replicated molecular finding is upregulation of neurotrophins. Landmark work by Dolotov et al. (2006) demonstrated that a single intranasal dose of Semax in rats produced approximately a 1.4-fold increase in BDNF protein, a 1.6-fold increase in TrkB phosphorylation, and up to a 3-fold increase in BDNF mRNA in the hippocampus within hours. Parallel increases in nerve growth factor (NGF) have also been reported. These changes promote conditions favorable for synaptic plasticity, long-term potentiation, dendritic spine formation, and neuronal survival.
Important Disclaimer
This content is provided solely for educational and research purposes. Semax is not approved for human therapeutic use outside of its registered indications in USA.





Reviews
There are no reviews yet.